Press Releases

Oasmia intends to issue convertible to replace current convertible loan

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) intends to issue a new convertible loan to replace the convertible loan (2016:1) in the total nominal amount SEK 28 million, which m...

Interim report for the period May 2016 – January 2017

Oasmia Pharmaceutical AB (publ) Interim report for the period May 2016 – January 2017 Strategic changes within Animal Health Division

Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors

Uppsala, Sweden March 1st, 2017 – Chairman Anders Lönner of Oasmia Pharmaceutical AB (NASDAQ: OASM) has announced his withdrawal from the board of directors, a decision that has raised numerous que...

Oasmia Pharmaceuticals Chairman Anders Lönner Resigns

Uppsala, Sweden February 28, 2017 – Chairman Anders Lönner of Oasmia Pharmaceutical AB (NASDAQ: OASM) has has informed the Nomination Committee that he does not wish to be re-elected as Chairman an...

Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division

Company intend to move veterinary assets to United States; plans new FDA study

Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)

Results from a dose-finding study with weekly administration of Apealea (alternatively branded Paclical in some international regions) in patients with metastatic breast cancer are now available.

Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed

Uppsala, Sweden, December 7, 2016 --- Oasmia Pharmaceutical (publ.) (”Oasmia” or ”The Company”) announces hereby that the previously announced warrant programs for the Oasmia management and Bo...

Interim report for the period May – October 2016

Expanded product portfolio and secured financing

Communiqué from Extraordinary General Meeting 2016

Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held on Monday, November 21, 2016, an Extraordinary General Meeting where the following main resolutions were made. For more detailed inf...

Nexttobe Extends Loan to Oasmia Pharmaceutical

Uppsala, Sweden, November 2, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extend...